ArticleClinical pharmacology and therapeutics2022

Disease Modeling and Model-Based Meta-Analyses to Define a New Direction for a Phase III Program of Gantenerumab in Alzheimer's Disease.

Sylvie Retout et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.